ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell Lymphoma

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519336-16-00

Enrollment

Registered

2024-12-05

Start date

2018-10-31

Completion date

2025-08-28

Last updated

2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Angioimmunoblastic T cell Lymphoma

Brief summary

Progression free survival (PFS)

Detailed description

Overall Survival (OS)

Interventions

DRUGBENDAMUSTINE HYDROCHLORIDE

DRUGAZACITIDINE

DRUGGEMCITABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS)	—

Secondary

Measure	Time frame
Overall Survival (OS)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026